Welcome to our dedicated page for Atara Biotherape news (Ticker: ATRA), a resource for investors and traders seeking the latest updates and insights on Atara Biotherape stock.
News about Atara Biotherapeutics, Inc. (NASDAQ: ATRA) centers on its development of allogeneic T-cell immunotherapies and the regulatory and business milestones associated with its Epstein-Barr virus (EBV)-specific platform. Atara describes itself as a leader in T-cell immunotherapy, focused on off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions, with headquarters in Southern California. Much of the company’s recent news flow has highlighted progress and challenges around tabelecleucel (tab-cel or EBVALLO), its EBV-specific T-cell therapy for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Investors following ATRA news can expect updates on FDA interactions, including Biologics License Application (BLA) submissions, Priority Review status, Prescription Drug User Fee Act (PDUFA) target action dates, and Complete Response Letters. Releases have detailed how Atara and its partner Pierre Fabre Laboratories addressed Good Manufacturing Practice (GMP) observations, transferred the tabelecleucel IND and BLA, and responded to evolving FDA positions on the adequacy of the pivotal ALLELE study for accelerated approval.
Company news also covers financial results and corporate restructuring, such as quarterly earnings releases, changes in research and development and general and administrative expenses, workforce reductions, lease amendments, and the impact of tabelecleucel-related milestone payments and commercialization revenue. In addition, Atara has issued updates on its strategic alternatives review, describing potential transactions it may consider to maximize shareholder value.
For readers tracking ATRA, this news stream provides insight into Atara’s clinical and regulatory trajectory, its partnership with Pierre Fabre Laboratories on tabelecleucel/EBVALLO, and the company’s evolving cost structure and strategic direction. Regularly reviewing these updates can help contextualize movements in ATRA stock and developments in the EBV-focused cell therapy space.
Atara Biotherapeutics has announced promising preclinical data for ATA3219, an allogeneic CD19-targeted CAR T therapy aimed at treating B-cell driven autoimmune diseases such as systemic lupus erythematosus (SLE) and multiple sclerosis (MS). The data, to be presented at the ISCT 2024 Annual Meeting, show that ATA3219 effectively depletes CD19+ B-cells and induces lower levels of pro-inflammatory cytokines compared to autologous CD19 CAR T cells.
ATA3219 incorporates multiple clinically validated technologies, including a modified CD3ζ signaling domain and a less differentiated phenotype. A Phase 1 clinical trial for lupus nephritis (LN) and severe SLE without lymphodepletion is expected to begin in Q4 2024, with initial data anticipated in 2025.
Atara Biotherapeutics has submitted a Biologics License Application (BLA) to the U.S. FDA for tabelecleucel (tab-cel®), targeting Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) in patients aged two and older.
This marks the first allogeneic T-cell therapy BLA submission for the FDA. If approved, tab-cel would be the first FDA-approved therapy for EBV+ PTLD, potentially triggering milestone payments of up to $80 million from Pierre Fabre Laboratories.
Supported by data from over 430 patients, including a 48.8% Objective Response Rate from the ALLELE study, tab-cel has shown a favorable safety profile. The BLA submission is part of a broader global partnership with Pierre Fabre, which includes double-digit tiered royalties on net sales and reimbursement for development costs.
Atara Biotherapeutics announced its first-quarter 2024 financial results and operational progress, highlighting key advancements in its lead CAR T program, ATA3219, for oncology and autoimmune diseases. The company plans to submit a BLA for tab-cel in Q2 2024 and initiate studies for lupus nephritis and non-Hodgkin’s lymphoma. Atara's cash runway extends into 2027, enabling key pipeline readouts.
Atara Biotherapeutics, Inc. granted 4,150 restricted stock units to a newly hired employee under the Nasdaq Listing Rule 5635(c)(4). The stock units vest over four years, subject to continuous employment.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.